IL-17 pathway inhibitor Vunakizumab for the treatment of systemic sclerosis: a single arm, open label trial

Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2025
This article has no abstract
Epistemonikos ID: 41c6c0b920c995c988c1bc80fc082692b155fc89
First added on: Mar 01, 2025